Navigation Links
SNM applauds FDA advisory committee recommendation for approval of Alzheimer's imaging agent
Date:1/24/2011

Reston, Va. (January 21, 2011) The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir. The agent, which is used in conjunction with positron emission tomography (PET) scans to detect beta amyloid plaques of the brain which may cause Alzheimer's disease, is produced by Eli Lilly and Company under the name Amyvid.

"For many years, the in vivo diagnosis of Alzheimer's disease has been a process of exclusion of other disorders that may affect cognition," said Karl Herholz, MD, president of SNM's Brain Imaging Council. "Now, for the first time, PET scans utilizing florbetapir will provide disease-specific inclusion criteria in the in vivo diagnosis of the disease."

PET scans performed with florbetapir will allow physicians to provide prognostic information to patients and their families even at a time of limited therapeutic approaches to treat Alzheimer's disease. In addition, the availability of imaging agents that can reliably detect amyloid plaques will be an absolute prerequisite to select patients that may benefit from future specific anti-amyloid based Alzheimer therapies.

"This recommendation of florbetapir is a huge step forward for the field of molecular imaging," noted Carolyn J. Anderson, PhD, president of SNM's Center for Molecular Imaging Innovation and Translation. "Researchers are continually working to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. It's wonderful to see molecular imaging playing such an important role in the molecular characterization of Alzheimer's disease. We are hopeful that this sets the stage for the approval of the many other molecular imaging agents for cancer, cardiovascular disease and other neurological diseases that are currently in clinical trials."

The FDA advisory committee approved florbetapir by a vote of 16-0 on the condition that training is provided to ensure physicians read the PET scans consistently and correctly. SNM and its Brain Imaging Council, in collaboration with other professional societies, are committed to developing PET imaging procedure guidelines and diagnostic scan interpretation educational tools to ensure that nuclear medicine physicians and radiologists will be proficient in performing and interpreting PET scans used in the diagnosis of Alzheimer's disease.

The FDA may or may not accept the opinion of the advisory committee.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. SNM applauds US Senates introduction of CARE Act
2. National Council Applauds Rep. Tonko for Seeking Strict Enforcement of Mental Health Parity Law – July 1, 2010 Deadline Approaching
3. Life Line Screening Applauds Rep. Paulsen on P.A.D. Resolution
4. ASTRO applauds MedPAC review of Stark law exception
5. ASTRO applauds nomination of Dr. Donald Berwick to head Centers for Medicare and Medicaid Services
6. SNM applauds temporary freeze on Medicare cuts
7. The Arc Applauds House Passage of Health Care Reform Legislation
8. Pew Applauds Federal Grant Program Supporting State Expansion of Evidence-Based Home Visitation
9. National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Reconciliation Bill
10. ISSA Applauds Cincinnati Trainer Anthony Reed for Dedication to Health Awareness
11. First Personal Injury Applauds HSE Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: